Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-612 Heterologous vs Homologous Booster Platform Trial
NCT05293665Phase 3Unknown
- Sponsor
- Vaxxinity
- Start
- Mar 2022
- Primary completion
- Nov 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
A Phase 3 trial of UB-612 in coronavirus disease 2019 (COVID-19), sponsored by Vaxxinity. Status: unknown.
02
Drugs
UB-612
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05293665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05293665.